Cardiac Dimensions
Cardiac Dimensions develops the Carillon Mitral Contour System, a less invasive treatment for functional mitral regurgitation, and is headquartered in Kirkland, Washington.
Overview of Cardiac Dimensions
Cardiac Dimensions is a medical device company headquartered in Kirkland, Washington. The company specializes in developing innovative treatments for heart failure, specifically functional mitral regurgitation (FMR). Their key product, the Carillon Mitral Contour System, offers a less invasive treatment option designed to align with the natural structure and function of the heart. Cardiac Dimensions has operations in the United States, Australia, and Germany.
Carillon Mitral Contour System
The Carillon Mitral Contour System, developed by Cardiac Dimensions, is a treatment specifically designed for functional mitral regurgitation (FMR). This system has received the CE Mark (0344), making it available for sale in Europe and other countries recognizing the CE Mark. In the United States, it is classified as an investigational device, with its use limited by law to investigational purposes. The Carillon System offers a less invasive alternative for patients with heart failure affected by FMR, aiming to work harmoniously with the heart's natural structure.
Global Operations
Cardiac Dimensions operates globally with significant presences in the United States, Australia, and Germany. The company is headquartered in Kirkland, Washington, where it coordinates its international activities and strategic market developments. Through these global operations, Cardiac Dimensions aims to broaden the availability and impact of its Carillon Mitral Contour System.
EMPOWER Trial in the United States
Cardiac Dimensions is currently enrolling patients in the pivotal EMPOWER Trial in the United States. This trial focuses on heart failure patients with large ventricles and functional mitral regurgitation. The overarching goal of the EMPOWER Trial is to further assess the effectiveness and safety of the Carillon Mitral Contour System, potentially leading to wider regulatory approval and clinical adoption in the U.S.